American Society of Hematology Annual Meeting

What is Cytoreduction in MPNs?

December 25th 2023, 10:00pm

Article

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.

High Responses to Jaypirca in Relapsed CLL With BTK Mutations

December 20th 2023, 2:00pm

Article

Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.

Study Shows Complete Response to Isa-KRD Treatment Combo in Multiple Myeloma

December 19th 2023, 2:00pm

Article

A treatment combination of Sarclisa, Kyprolis, Revlimid and dexamethasone demonstrated a complete response in patients who were newly diagnosed with multiple myeloma.

Scemblix Shows Greater Efficacy, Safety For Patients With Chronic Phase CML

December 17th 2023, 2:00pm

Article

A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

Conference Highlights from the 2023 ASH Annual Meeting

December 14th 2023, 4:00pm

Podcast

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

Lost-Lasting Responses With Yescarta for High-Risk Large B-Cell Lymphoma

December 13th 2023, 10:00pm

Article

Updated safety and subgroup analyses appear consistent with previously reported results from the phase 2 ZUMA-12 study of Yescarta for patients with high-risk large B-cell lymphoma.

Expert Hopes to See New Drug Combinations for MPNs in 2024

December 13th 2023, 4:00pm

Article

Dr. Lucia Masarova sat down with CURE® and discussed the advancements she hopes to see in 2024 for the treatment of patients with myeloproliferative neoplasms.

MRD Negativity May Be Achievable With Revumenib in Some Leukemia Subset

December 12th 2023, 10:00pm

Article

Children and adults with relapsed/refractory KMT2A rearranged acute leukemia may obtain promising response rates with revumenib, a novel targeted therapy.

Financial Navigation Programs Are ‘Efficient’ for Some With Multiple Myeloma

December 12th 2023, 8:00pm

Article

Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity.

Novel Drug Has Survival Benefit in Stem Cell Transplant-Related GVHD

December 12th 2023, 4:00pm

Article

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.